15 Oct Corenza-c® Effervescent Tablets (C661 (Act 101/1965)): Amendment to Product Labelling – Not to Be Used in Children Under 12 Years of Age
Posted at 11:05h
in
Adcock Ingram Limited, in collaboration with the South African Health Products Regulatory Authority (SAHPRA), would like to inform you of the amended product labelling for Corenza-C® Effervescent Tablets to align with the recommended contraindicated use of aspirin in children under the age of 12 years because of the risk of Reye’s Syndrome.
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
15/10/2025
File Type:
pdf
Category:
Communication To Health Care Professionals